Edesa Biotech is trading 5.3% lower at $2.16, with the specific reason for today’s decline unconfirmed.
- No verified November 4 company-specific catalyst surfaced in the available search.
- The company’s recent major announcement was FDA clearance for a Phase 2 vitiligo study, published October 15, with topline data anticipated in Q4 2027.
- The broader market and biotech sector are higher; shares have fallen across several recent sessions, but neither provides a clear explanation.